Stay updated with breaking news from Structurally Targeted Allosteric Regulator. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
23.03.2023 - Company expects completion of IND-enabling studies of GT-02287 in H1 2023Submission of dossier to start Phase 1 clinical trial of GT-02287 in GBA1 Parkinson’s Disease expected by mid-year 2023$22.1 million in cash and cash equivalents and marketable ...
Company expects completion of IND-enabling studies of GT-02287 in H1 2023Submission of dossier to start Phase 1 clinical trial of GT-02287 in GBA1 Parkinson’s Disease expected by mid-year... | March 23, 2023
Accumulating Preclinical Data Provide Further Support for Disease-Modifying Potential of Brain Penetrant Investigational Small Molecule Therapeutic,...
Gain Therapeutics Presents New Preclinical Data Showing Promising Pharmacological Activity in Parkinson’s Disease Patient-Derived Dopaminergic Neurons - read this article along with other careers information, tips and advice on BioSpace
GAIN THERAPEUTICS, INC. REPORTS second QUARTER 2022 FINANCIAL RESULTS AND BUSINESS UPDATE Presented Additional Supportive Preclinical Data for... | August 8, 2022